* Cohort 1 - Non-operable patients
* Patients aged at least 18 years old and ≤ 70 years old; male or female.
* AND available biopsy
* AND Karnofsky index ≥ 50% at Screening
* Cohort 2 - Elderly patients
* Patients aged > 70 years old; male or female
* AND Balducci score I or II. For patients classified in Balducci II, only light Balducci II will be included, as defined by a Charlson score <4 and a score of autonomy IADL = 4. In the oncogeriatric evaluation, symptoms related to brain cancer disease have not to be considered for this criterion.
* Karnofsky score (KPS) of ≥ 70% at Screening
* Regardless resection
* MRI at maximum 48h00 after surgery if partial, subtotal or macroscopically complete or supra-total resection
* For both cohorts
* Histologically confirmed diagnosis of glioblastoma (GBM) (2016 OMS classification) (Louis et al., 2016).
* Contrast enhancing disease on MRI within 14 days prior to screening.
* Within 2 weeks of baseline visit, hematologic and renal functions as specified: Absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hgb ≥ 9.0g/dL, creatinine ≤ 1.7mg/dl, total bilirubin ≤ 1.5mg/dL, blood urea nitrogen (BUN) within 2 times the upper limit of normal, transaminases ≤ 4 times above the upper limits of the institutional norm.
* Sexually active patients must use an acceptable method of contraception while receiving doses of study medication.
* Females of childbearing potential must have a negative serum or urine pregnancy test at screening and have additional pregnancy tests during study.
* Patient who cannot undergo MRI
* Pregnant or lactating woman.
* Serious concurrent infection or medical illness that would jeopardize the ability of the patient to receive study treatment with reasonable safety.
* Patients with previous cancer (< 5 years) except basocellular skin tumors and in situ cervix tumor
* Patient has a known hypersensitivity to crocetins, L-TC or any of its excipients.
* Contraindication of temozolomide as described in the Summary of product characteristics.
* Patient who cannot understand French language.
* Patient without French National Health insurance
* Patient who cannot be reliable for follow-up
* Patient under law protection